KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

Rhea-AI Summary

KalVista Pharmaceuticals (NASDAQ: KALV) has announced a virtual investor event focused on the commercialization strategy for sebetralstat, their investigational treatment for hereditary angioedema (HAE).

The webcast is scheduled for Tuesday, March 25, 2025, from 8:00 AM to 10:00 AM ET. The event will feature presentations from KalVista's management team and leading HAE experts who will discuss:

• Current HAE treatment guidelines
• Unmet needs for HAE patients
• Potential of sebetralstat as a new treatment option

The event will include a live Q&A session and can be accessed through the Investors section at ir.kalvista.com. A replay will be available after the event.

Webcast scheduled for Tuesday, March 25 at 8:00 am ET

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will host a virtual event to provide an overview of the commercialization strategy, plans and progress for sebetralstat, the Company’s investigational treatment for hereditary angioedema (HAE). The event will take place on Tuesday, March 25, 2025, from 8:00 a.m. to 10:00 a.m. ET. To register, please click here.

In addition to presentations by KalVista’s management team, leading external experts in HAE will discuss the current treatment guidelines and unmet needs for people living with HAE, and how sebetralstat could provide a new treatment option. A live question-and-answer session will follow the formal presentations.

The live webcast and accompanying slides will be accessible through the Investors section of the Company’s website at ir.kalvista.com. A replay of the webcast will be available following the event.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA, with a PDUFA goal date of June 17, 2025. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities.

For more information about KalVista, please visit www.kalvista.com or follow us on social media at @KalVista and LinkedIn.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250310210573/en/

Ryan Baker

Head, Investor Relations

(617) 771-5001

ryan.baker@kalvista.com

Molly Cameron

Director, Corporate Communications

(857) 356-0164

molly.cameron@kalvista.com

Source: KalVista Pharmaceuticals, Inc.

FAQ

When is KalVista's (KALV) investor webcast for sebetralstat commercialization?

KalVista's investor webcast is scheduled for Tuesday, March 25, 2025, from 8:00 AM to 10:00 AM ET.

What will be discussed in KalVista's (KALV) upcoming investor webcast?

The webcast will cover sebetralstat's commercialization strategy, plans, and progress as a treatment for hereditary angioedema (HAE), featuring presentations from management and HAE experts.

How can investors access KalVista's (KALV) sebetralstat commercialization webcast?

Investors can access the webcast through KalVista's website at ir.kalvista.com in the Investors section, with replay available after the event.

What is the therapeutic focus of KalVista's (KALV) sebetralstat drug?

Sebetralstat is an investigational treatment being developed for hereditary angioedema (HAE).